Nickan Research Institute Journal of Parathyroid Disease 2345-6558 11 1 2023 01 01 Sonidegib induced rhabdomyolysis in kidney transplant patient: a case report e11204 e11204 10.34172/jpd.2023.11204 EN Sonila Mocka https://orcid.org/0000-0001-8627-3971 Stefano Ferraro Michela Ardini Michele Marchini Laura Panaro Matteo Trezzi Davide Rolla Journal Article 10.34172/jpd.2023.11204 2023 04 17 2023 06 05 Kidney transplant recipients (KTR) have a higher risk of developing malignancies compared to the general population, due to the immunosuppressive regimens which can promote the oncogenesis process. The incidence of de novo non-melanoma skin cancer (NMSC) in KTR is greater than in the general population. Basal cell carcinoma (BCC) represents one of the most frequent malignancies in KTR. Sonidegib is a Hedgehog signaling pathway inhibitor approved for the treatment of locally advanced basal-cell carcinoma (LABCC) that following surgery or radiation therapy, or is given to those candidates who are not eligible to surgery or radiation therapy. This paper reports the case of a kidney transplant patient, who developed severe acute kidney injury (AKI) due to rhabdomyolysis (RML) induced by sonidegib therapy which required renal replacement therapy (RRT).